Jag Capital Management LLC Buys Shares of 1,322 TransMedics Group, Inc. (NASDAQ:TMDX)

Jag Capital Management LLC bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 1,322 shares of the company’s stock, valued at approximately $208,000.

Other institutional investors have also modified their holdings of the company. Vaughan Nelson Investment Management L.P. purchased a new stake in shares of TransMedics Group in the 2nd quarter valued at approximately $39,862,000. Driehaus Capital Management LLC lifted its holdings in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Principal Financial Group Inc. grew its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares during the period. Hood River Capital Management LLC acquired a new stake in TransMedics Group during the second quarter worth $18,854,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $16,086,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now directly owns 732 shares in the company, valued at approximately $61,158.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Edward M. Basile sold 6,750 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total value of $1,144,623.75. Following the completion of the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,958 shares of company stock worth $5,230,528 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Stock Up 1.1 %

Shares of NASDAQ TMDX opened at $86.95 on Monday. TransMedics Group, Inc. has a 12-month low of $56.83 and a 12-month high of $177.37. The stock has a market cap of $2.92 billion, a P/E ratio of 91.47 and a beta of 2.08. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business’s fifty day simple moving average is $132.03 and its 200-day simple moving average is $139.89.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. TransMedics Group’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, equities analysts predict that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TMDX. Robert W. Baird cut their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Needham & Company LLC reduced their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. JPMorgan Chase & Co. decreased their price objective on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a report on Tuesday, October 29th. Canaccord Genuity Group cut their target price on TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, Morgan Stanley upped their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $144.80.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.